This content is only available within our institutional offering.

05 Apr 2022
PANMURE: Faron Pharmaceuticals : Focus on bexmarilimab

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
PANMURE: Faron Pharmaceuticals : Focus on bexmarilimab
Faron Pharmaceuticals Oy (FARN:LON) | 178 0 0.0% | Mkt Cap: 201.6m
- Published:
05 Apr 2022 -
Author:
Dr Mike Mitchell | Julie Simmonds -
Pages:
8 -